Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Jan;63(1):14-6.
doi: 10.1002/hep.28224. Epub 2015 Oct 30.

Flunarizine arrests hepatitis C virus membrane fusion

Daniil M Prigozhin  1 , Yorgo Modis  1
Affiliations
Editorial

Flunarizine arrests hepatitis C virus membrane fusion

Daniil M Prigozhin et al. Hepatology. 2016 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Potential conflict of interest: Nothing to report.

Figures

Fig. 1
Fig. 1
The chemical structure and activity of flunarizine. (A) Flunarizine is a large hydrophobic fluorinated piperazine derivative used in the prophylaxis of migraine. Its activity is based on blocking calcium influx into vascular smooth muscle. In an article in the current issue of Hepatology, Perin et al. report that flunarizine also blocks the HCV lifecycle at the membrane fusion step. (B) Fluphenazine, pimozide, and trifluoperazine form a subset of related calcium antagonists that show similar ability to inhibit HCV entry as flunarizine and are likely to share the inhibitory mechanism of flunarizine.
See this image and copyright information in PMC

Comment on

References

    1. Lindenbach BD, Murray CL, Thiel HJ, Rice CM. Flaviviridae. In: Knipe DM, Howley PM, editors. Fields Virology. Sixth ed. Vol. 1. Philadelphia: Lippincott Williams & Wilkins; 2013. pp. 712–746.
    1. Lindenbach BD, Rice CM. The ins and outs of hepatitis C virus entry and assembly. Nat Rev Microbiol. 2013;11:688–700. - PMC - PubMed
    1. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015;63:199–236. - PubMed
    1. Kong L, Giang E, Nieusma T, Kadam RU, Cogburn KE, Hua Y, Dai X, et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science. 2013;342:1090–1094. - PMC - PubMed
    1. Khan AG, Whidby J, Miller MT, Scarborough H, Zatorski AV, Cygan A, Price AA, et al. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature. 2014;509:381–384. - PMC - PubMed

MeSH terms